Hypoxic injury provokes inflammation of many tissues including the ocular surface. In rabbit corneal epithelial cells, both peroxisome proliferator-activated receptor (PPAR)-inducible cytochrome P450 4B1 and cyclooxygenase-2 (COX-2) mRNAs were increased by hypoxia. PPAR ␣ and ␤ but not ␥ mRNAs were detected in these cells. The PPAR activator, WY-14,643 increased COX-2 expression. Similarly, non-steroidal anti-inflammatory drugs with the ability to activate PPARs induced COX-2 independently of prostaglandin synthesis inhibition. COX-2 protein overexpression by hypoxia and PPAR activation was not associated with a parallel increase in prostaglandin E 2 accumulation. However, the enzyme regained full catalytic activity when: 1) hypoxic cells were re-exposed to normoxic conditions in the presence of heme and arachidonic acid, and 2) WY-14,643-treated cells were depleted of intracellular GSH. Consistent with previous observations showing that the corneal production of cytochrome P450-derived inflammatory eicosanoids is elevated by hypoxia and inflammation, the current data suggest that hypoxic injury is a model of inflammation in which molecules other than COX-derived arachidonic acid metabolites play a major proinflammatory role. This study also suggests that increased cellular GSH may be the mechanism responsible for the characteristic dissociation of PPAR-induced COX-2 expression and activity. Moreover, we provide new insights into the commonly observed lack of efficacy of classical non-steroidal anti-inflammatory drugs in the treatment of hypoxia-related ocular surface inflammation.
Eye closure during sleep as well as contact lens wear creates an environment that has been described as a state of subclinical inflammation characterized by corneal swelling, conjunctival vasodilation, and significant levels of polymorphonuclear leukocytes in the tear film. These changes are attributed to reduced oxygen and carbon dioxide exchange, leading to corneal hypoxia and subsequent acidosis (1) .
There exist a host of mediators that have been implicated in the development and progression of corneal inflammation (2, 3) . The source of these mediators may be the injured tissue or infiltrating inflammatory cells. Although the progression of an inflammatory response is generally dependent on the inflammatory infiltrate, its initiation is usually the result of inflammatory mediators released from the damaged tissue. Among the endogenous corneal inflammatory mediators released from the epithelium are the arachidonic acid-derived eicosanoids, which have been implicated in the initiation, development, and progression of an inflammatory response (4, 5) . The relative contribution of each eicosanoid to this reaction is unclear. These eicosanoids are produced by the activity of cyclooxygenase (COX) 1 (primarily PGE 2 ), lipoxygenase (12(S)-HETE and leukotrienes, e.g. LTB 4 ) and cytochrome P450 monooxygenase (12(R)-HETE and 12(R)-HETrE) (6) .
We have previously demonstrated that 12(R)-HETE and 12(R)-HETrE possess potent inflammatory properties with 12(R)-HETrE being a powerful angiogenic factor and that both metabolites assume the role of inflammatory mediators in hypoxia-and alkali-induced injury in the cornea, in vivo (7, 8) . Additional studies using in vitro models of corneal epithelial injury further support a relationship between injury, hypoxia, and the production of the CYP-derived eicosanoids (9) . Studies to identify the CYP isoform responsible for the production of 12(R)-HETE and 12(R)-HETrE revealed that a CYP4B1 isoform is readily induced in response to hypoxia in vitro and in vivo and that antibodies against this isoform inhibited the synthesis of these eicosanoids (10) .
Hypoxia and cellular injury provoke the induction of COX-2 in many cell types (11, 12) . Moreover, induction of COX-2 mRNA and protein together with increasing levels of prostanoids, mainly PGE 2 , is the hallmark of inflammation in many tissues (13, 14) . Among the factors associated with the transcriptional activation of COX-2 are the PPARs. These are nuclear hormone receptors that regulate gene transcription in response to peroxisome proliferators and fatty acids, including certain PGs, HETEs, as well as some of the commonly used non-steroidal anti-inflammatory drugs (NSAIDs) (15, 16) . PPAR ligands activate transcription of COX-2 as well as the transcription of several CYP4 genes, including CYP4B1 (17) (18) (19) . Hence, we carried out studies to determine the involvement of COX-2 in hypoxia-induced injury of the corneal epithelium and to examine its relation to PPAR activation and CYP4B1 expression.
EXPERIMENTAL PROCEDURES
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§ To whom correspondence should be addressed. Tel.: 914-594-4153; Fax: 914-594-4303; E-mail: michal_schwartzman@nymc.edu. a mixture of Dulbecco's modified Eagle's medium/F-12 (1:1) in the presence of 10% fetal bovine serum and 1% antibiotic/antimycotic mixture (Fungizone, Life Technologies, Inc.); 48 h before the experiment, the medium was changed to Dulbecco's modified Eagle's medium/F-12 containing 0.4% fetal bovine serum and antibiotics. Cells were then washed twice with 2 ml of sterile phosphate-buffered saline and incubated with 2 ml of serum-free medium containing antibiotics with and without PPAR ligands or COX inhibitors under normoxia (5% CO 2 , 95% air (ϳ20% O 2 )) or in a modular tissue culture chamber (Billups-Rothenburg, Del Mar, CA) supplied continuously with 5% CO 2 , 0% O 2 , 95% N 2 (hypoxia) and bubbled through deionized H 2 O into the chamber within a 37°C incubator for an additional 2-24 h. In some experiments, cells were incubated with L-buthionine-[S,R]sulfoximine (BSO, 1 mM) and maleic acid diethylester (DEM, 1 mM) for 18 h to deplete intracellular GSH.
Western Blot Analysis-Protein content was determined using the DC Protein Assay (Bio-Rad) with bovine serum albumin as the standard. Cell lysates (30 g of protein) were mixed with Laemmli reagent (final concentration 1%, w/v, sodium dodecyl sulfate; 10%, v/v, glycerol; 0.5%, w/v, bromphenol blue) under reducing conditions (4%, v/v, ␤-mercaptoethanol) and heated for 5 min at 85°C. SDS-polyacrylamide gel electrophoresis was performed using 10% (w/v) and 3% (w/v) acrylamide for separating gel and stacking gel, respectively. Protein transfer onto polyvinylidene difluoride membranes (Amersham Pharmacia Biotech) was performed at 16 V for 1 h. Membranes were saturated in blocking buffer containing 5% nonfat dry milk and incubated for 2 h at room temperature with the following polyclonal antibody preparations: rabbit anti-murine COX-2, goat anti-human COX-1, rabbit anti-human HO-1, or rabbit anti-human HO-2. After washing with buffer (Tris/HCl, 0.42%, pH 7.4, containing 0.1% Tween 20), membranes were further incubated with an anti-rabbit or anti-goat IgG conjugated with horseradish peroxidase (Santa Cruz Biotechnology, Santa Cruz, CA) at dilution 1:4,000 for 45 min at room temperature. Immunoreactive proteins were detected using chemiluminescence substrates according to the manufacturer's instructions and were visualized after exposure to Hyperfilm TM ECL (Amersham Pharmacia Biotech). Quantitation was performed by scanning the blot into Photoshop and performing densitometry with NIH Image.
Measurements of PGE 2 Levels-At the end of the incubation period, the medium was collected and stored at Ϫ80°C. Solid phase enzyme immunoassay (Cayman Chemical, Ann Arbor, MI) was performed as suggested by the manufacturer. PGE 2 levels were determined using a standard curve and a linear log-logit transformation.
Measurements of Cyclooxygenase Activity-Cells were incubated under normoxia or hypoxia or treated with WY-14,643 (100 M) for 12 and 24 h in a serum-free medium. Cells were then washed twice with phosphate-buffered saline and further incubated with arachidonic acid (10 M) in the presence or absence of heme (2 M), NS398 (1 M), indomethacin (5 M), or GSH (10 -50 mM) for 1 h in an oxygenated incubator. PGE 2 levels in the medium were measured by enzyme immunoassay as described above.
Reverse Transcription-Polymerase Chain Reaction (RT-PCR)-Total RNA was isolated with TRIzol reagent (Life Technologies, Inc.) and quantified spectrophotometerically. RT reaction was performed with 5 g of total RNA and an oligo(dT) primer using the First-Strand cDNA synthesis kit (Amersham Pharmacia Biotech). For amplification of 28 S rRNA and PPARs (␣, ␤, ␥), a specific backward primer was used in the single reaction. The reaction mixture was then subjected to brief incubation at 65°C in order to inactivate the enzyme. PCR reactions were carried out in a final volume of 100 l consisting of 20 mM Tris-HCl, pH 9.0, 2 mM MgSO 4 , 200 M amounts of each deoxyribonucleoside triphosphate, 4 l of the RT first-strand cDNA product, 0.2 M of each forward and reverse primer, and 2.5 units of Pfu Turbo DNA polymerase (Stratagene, La Jolla, CA). The reactions were heated to 97°C for 1 min and then immediately cycled 30 or 35 times through a 1-min denaturing step, 1.5-min annealing step at 50 or 55°C, and a 2-min extension step at 72°C. After the cycling procedure, a final 10-min elongation step at 72°C was performed. The following primers were used: CYP4B1 primers, 4B1-F (5Ј-TCTCTGGGTTGGACAGTTCATTG) and 4B1-R (5Ј-TG-TCTCCTTTGCCAAACGTACAC); COX-2 primers, COX-2F (5Ј-GCCC-TTCCTCCTGTGGCTGAT) and COX-2R (5Ј-TTGAGCACATCGCACA-CTCT); 28 S rRNA primers, 28 S rRNA-F (5Ј-AAACTCTGGTGGAGG-TCCGT) and 28 S rRNA-R (5Ј-CTTACCAAAAGTGGCCCACTA). Primers for the different PPARs were designed as described previously (21) .
Northern Analysis-Total RNA (10 g) was separated on a 1% agarose gel containing formaldehyde, visualized by ethidium bromide staining, and transferred overnight to Hybond N plus membranes (Amersham Pharmacia Biotech) through capillary blotting. The membranes were probed with 32 P-labeled cDNA probes in Rapid-Hyb hybridization buffer (Amersham Pharmacia Biotech). The rabbit COX-2 cDNA probe was obtained from Dr. M. Breyer, Vanderbilt University (22) . The rabbit 28 S rRNA probe was generated by PCR as described above. The resulting blots were subjected to autoradiography with NEF reflection autoradiography films (NEN Life Science Products). Densitometry analysis was done as described for the Western blot.
Statistical Analysis-Analysis of variance and Student's t test for unpaired data were used to evaluate differences among control and treated samples. A p value less than or equal to 0.05 was considered significant. Unless stated otherwise, results are presented as means Ϯ S.E.
RESULTS
COX-2 is induced in many cell types in response to injury, growth factors and cytokines. In this respect, RCE cells exhibit a similar response; COX-2 protein levels are markedly increased by 2-3-fold in response to these stimuli (data not shown). Hypoxic injury is considered an inflammatory stimulus in many tissues. In RCE cells, hypoxia, caused a 3-fold increase in COX-2 protein levels within 24 h (Fig. 1A) . The effect of hypoxia on COX-2 protein was time-dependent and correlated with the increasing levels of COX-2 mRNA (Fig. 1B) . CYP4B1, a cytochrome P450 protein whose expression has been correlated with the synthesis of the inflammatory eicosanoids 12(R)-HETE and 12(R)-HETrE by the corneal epithelium (10), showed a similar time course of expression in response to hypoxia (data not shown).
The transcriptional activation of COX-2 and CYP4B1 following hypoxia may share a common mechanism; both have been shown to be activated by PPAR ligands. As seen in Fig. 2A , RT-PCR of RCE cell mRNA revealed the presence of PPAR␣ and PPAR␤ transcripts but no transcript for PPAR␥. Control experiments indicated that the expression of PPARs ␣, ␤, and ␥ was readily detected in rabbit liver RNA (Fig. 2B) . The specificity of these PCR products (corneal epithelial PPAR ␣ and ␤) was further demonstrated by restriction analysis based on the published sequences of the rabbit PPARs (21) .
We further examined the effect of common peroxisome proliferators as well as NSAIDs that have been shown to act as PPAR ligands (23) on COX protein levels. As seen in Fig. 3A , the commonly used PPAR ligand, WY-14,643, greatly increased COX-2 protein levels. WY-14,643 was more potent than clofibrate; its addition to the medium caused a 2-fold increase in COX-2 protein (Fig. 3A) , while clofibrate increased COX-2 protein by about 30% (data not shown). Under hypoxic conditions, addition of WY-14,643 did not produce an additional significant increase in COX-2 levels (Fig. 3A) , suggesting that hypoxia and the PPAR ligand may share a common mechanism for induction of COX-2. Indomethacin as well as flurbiprofen significantly increased COX-2 protein levels by about 2-fold. Aspirin at a concentration of 100 M also increased COX-2 protein levels (data not shown). Similar to WY-14,643, addition of these NSAIDs to hypoxia-treated cells did not cause a further increase in COX-2 protein levels (data not shown). Neither hypoxia nor WY-14,643 or NSAIDs changed the level of the constitutively expressed COX-1 protein (Fig. 3A) . Actinomycin D inhibited COX-2 expression when used in combination with hypoxia, indomethacin, and WY-14,643 (Fig. 3B) , further indicating that COX-2 is transcriptionally activated under these conditions. Indeed, Northern analysis demonstrated that addition of WY-14,643 resulted in a 2-fold increase in COX-2 mRNA (Fig. 4) . Indomethacin at 30 M, while increasing COX-2 protein levels (Fig. 3A) and COX-2 mRNA (data not shown), inhibited PGE 2 levels by 60% and 80% in cells grown under normoxic and hypoxic conditions, respectively. The effect of indomethacin on COX-2 protein levels was not reversed by addition of exogenous PGE 2 . In fact, addition of exogenous PGE 2 to normoxia-and indomethacin-treated cells had little or no effect on COX-2 protein levels (Fig. 5) , suggesting a dissociation between COX-2 expression and PGE 2 levels. Similar results were obtained in hypoxia/indomethacin-treated cells (data not shown).
The increase in COX-2 protein levels in response to hypoxia or WY-14,643 was not associated with a comparable increase in PGE 2 levels (Fig. 6A) . In fact, marked 65% and 64% decreases in PGE 2 levels were observed in cells grown under hypoxic conditions for 12 and 24 h, respectively. In WY-14,643-treated cells for 12 h PGE 2 levels were similar to the control levels; however, at 24 h the levels were significantly reduced by 25% as compared with control cells (Fig. 6A) . Cells grown under hypoxic conditions and treated with WY-14,643 showed a similar decrease in PGE 2 levels to that in hypoxia, namely 701 Ϯ 53, 448 Ϯ 63, and 438 Ϯ 61 pg PGE 2 /ml in normoxia, hypoxia, and hypoxiaϩWY-14,643, respectively. These results are similar to that obtained for the protein where no additive effect for hypoxia and WY-14,643 was observed (Fig. 3A) . There are several possibilities that could account for the decreased PGE 2 levels. One is a lack of substrate, arachidonic acid, which has been long considered as the rate-limiting step in prostaglandin synthesis. Addition of 10 M arachidonic acid to hypoxia or WY-14,643-treated cells during the culture period restored the levels of PGE 2 accumulation to that seen in cells incubated under normoxic conditions (Fig. 6B) . However, the increase in PGE 2 levels in cells supplemented with arachidonic acid did not reflect the 2-4-fold increase in COX-2 protein seen in cells incubated under the same conditions (Figs. 1 and 3) .
Another possibility is that the induced COX-2 protein is defective or is inactive due to a lack of cofactors such as heme. In many cells, the level of heme is regulated by the activity of heme oxygenase (HO), specifically the inducible isoform, HO-1. Western blot analysis revealed that only hypoxic conditions caused a marked increase in HO-1 protein levels (Fig. 7) . WY-14,643 and indomethacin, while increasing COX-2 protein, had no effect on HO-1 protein level. In all experimental conditions, the protein levels of the constitutively expressed isoform, HO-2, remained unchanged (Fig. 7) . These results suggest that, at least in hypoxia, a shortage of cellular heme may contribute to the decrease in PGE 2 levels. The reduced PGE 2 levels in hypoxia-treated cells may also stem from lack of oxygen. However, neither heme nor oxygen can account for the relatively depressed PGE 2 in WY-14,643-treated cells.
It is well documented that the catalytic activity of COX isoforms requires the presence of hydroperoxides (24) . On the other hand, conditions of oxidative stress such as those associated with hypoxia and inflammatory processes are associated with increased expression of GSH-dependent peroxidase (25) . Glutathione peroxidase as well as GSH itself have been shown to inhibit COX-1 and COX-2 catalytic activity (26) . To evaluate whether changes in GSH levels underlie the decrease in PGE 2 levels, cells were incubated with BSO and DEM to deplete , and 24 h. Northern blot analysis of total RNA was performed using the rabbit COX-2 cDNA and 28 S rRNA probes. Results are the mean Ϯ S.E., n ϭ 3; *, p Ͻ 0.05 from control normoxia; E, control; , WY-14,643.
endogenous GSH under hypoxia and with the addition of WY-14,643. As seen in Fig. 8 , depletion of GSH increased PGE 2 levels by 8-, 2-and 14-fold in normoxia-, hypoxia-, and WY-14,643-treated cells, respectively. Moreover, PGE 2 accumulation in WY-14,643-treated cells was well correlated with the increased COX-2 protein expression. In contrast, measurement of COX activity as the conversion of arachidonic acid to PGE 2 in 1 h in the presence of exogenous GSH demonstrated a concentration-dependent inhibition of COX activity (30% and 40% inhibition at 10 and 50 mM GSH, respectively).
We further examined COX activity in cells grown for 12 or 24 h in hypoxia or normoxia and in cells treated with WY-14,643 and subsequently incubated under normoxia with 10 M arachidonic acid and 2 M heme for 1 h. As seen in Fig. 9 , in 12-and 24-h hypoxia-treated cells COX activity was 2 and 5 times higher than that of the control cells, respectively, further indicating that the increased immunoreactive COX-2 protein is an active enzyme and that oxygen is a major limiting factor. However, COX activity in cells treated with WY-14,643 remained low and was about 50% of the activity measured in control cells (Fig. 9) . Finally, addition of the selective COX-2 inhibitor, NS398, to the incubation medium revealed that about 50% of the COX activity in cells incubated under normoxic condition is driven by COX-2, while in hypoxia-treated cells or cells treated with WY-14,643, this activity accounts for almost 100% (Fig.  10) suggesting that, although COX-1 protein level remains unchanged, its activity was diminished following hypoxia and WY-14643 treatment.
DISCUSSION
Early prostaglandin research strove to establish a link between their synthesis and ocular inflammation. It is well documented that corneal surface injury increases production of cyclooxygenase-derived eicosanoids (PGI 2 , PGF 2␣ , PGE 2 , PGD 2 , and thromboxane A 2 ) by the corneal epithelium (27) . There are, however, several observations that challenge the significance of their role in the inflammatory response. The increase in the production of these eicosanoids correlates poorly to the inflammatory sequelae (28) . Moreover, while topical applications of micromolar concentrations of these eicosanoids are required to elicit inflammatory effects, much lower concentrations are usually recovered at the site of surface injury (29, 30) . Furthermore, the use of metabolic inhibitors against the cyclooxygenase pathway is not as efficacious as corticosteroids in the treatment of ocular surface inflammation (31, 32) . These inhibitors tend to have partial efficacy at best, indicating that other corticosteroid-sensitive mediators may participate in the corneal inflammatory response. Studies in our laboratory identified the formation of the CYP-derived arachidonic acid metabolites 12(R)-HETE, a Na,K-ATPase inhibitor with chemotactic activity, and 12(R)-HETrE, a powerful proinflammatory mediator that has been shown to stimulate vasodilation, increase anterior chamber proteins, chemoattract polymorphonuclear leukocytes, and elicit angiogenesis (see Ref. 6 and references therein). The endogenous conversion of arachidonate to these metabolites is increased following hypoxia in vitro and in vivo and after chemical injury in vivo. Their production rate correlates with the inflammatory response in vivo and inhibition of their formation attenuates the inflammation (reviewed in Ref. 6 ). In all, these studies clearly place the CYP-derived 12-hydroxyeicosanoids as corneal epithelial-derived mediators of ocular surface inflammation. However, the discovery of COX-2 as the inducible isoform of cyclooxygenase that is differently affected by common NSAIDs brought back the question of the involvement of prostaglandins in the ocular inflammatory process. The contemporary view is that prostaglandins are mediators of numerous biological processes including inflammation (33) .
In the present study we examined the presence and inducibility of COX-2 in corneal epithelial cells following hypoxiainduced injury; such injury has been associated with a severe inflammatory response in vivo and with increased production of 12-HETE and 12-HETrE in vivo and in vitro (7) . We found that COX-2, but not COX-1, mRNA and protein levels are markedly increased in RCE cells following hypoxia. Hypoxia has been shown to stimulate the expression of COX-2 in the lung and endothelial cells (11, 12, 34) . While acute exposure (2 h) to hypoxia increased COX activity in endothelial cells (35) , chronic exposure (24 h) in these cells and in alveolar macrophages resulted in decreased COX-2 protein and PGE 2 synthesis (36, 37) . In our study, 12-24 h of hypoxia markedly decreased PGE 2 accumulation while increasing COX-2 expression. The use of the selective COX-2 inhibitor NS-398 further suggested that COX activity in hypoxic cells is essentially that of COX-2, whereas in control (normoxia) cells, both COX-1 and COX-2 contributed equally to the production of PGE 2 .
Recent studies demonstrated that a CYP4B1 isoform is induced in the corneal epithelium in response to hypoxia and is involved in the production of 12-HETE and 12-HETrE (10). A similar pattern of induction was observed in RCE cells. The increased CYP4B1 and COX-2 mRNA levels suggest a common mechanisms for regulation. Indeed, the rabbit lung CYP4B1 has been shown to be activated by clofibrate, a PPAR activator (15) . Likewise, COX-2 expression has been shown to be induced by numerous PPAR ligands (17) . Moreover, clofibrate increased conversion of arachidonic acid to 12-HETE and 12-HETrE in the corneal epithelium (10) tional activator of COX-2 expression in response to hypoxia (11) . The observation that these NSAIDs did not decrease COX-2 expression under hypoxic conditions argues against a dependence on NFB in the hypoxia-induced expression of COX-2. In all, these findings suggest the possibility that PPAR activation, at least in part, contributes to the hypoxia-induced expression of COX-2 and CYP4B1. To this end, addition of PPAR ligands to hypoxia-treated cells did not yield a further increase in either COX-2 protein, mRNA, or PGE 2 accumulation, suggesting that hypoxia and PPAR ligands may share a similar mechanism, e.g. PPAR activation, by which they transcriptionally activate COX-2 expression.
Noteworthy is the fact that the increased expression of COX-2 after addition of a PPAR ligand was, as in hypoxia, associated with a decrease in PGE 2 accumulation. However, while COX enzymatic activity in hypoxic cells could be fully expressed, when oxygen is replenished, to reflect the 3-4-fold increase in protein levels, it was just about 50% of control in cells treated with WY-14,643. Ledwith et al. (39) have shown that PPAR ligands, including WY-14643, cause little or no increase in PGE 2 levels in mouse liver cells, while markedly increasing COX-2 expression. These authors demonstrated that PPAR ligands do not inhibit COX enzymatic activity and suggested that these agents exhibit an indirect inhibitory effect on COX activity. Our findings concur with this report; however, they also offer a potential mechanism for WY-14,643. As indicated before, GSH peroxidase exerts a regulatory control on COX activity (26) . Depletion of GSH in cells treated with WY-14,643 restored COX activity and increased it to levels that better reflected the increase in protein expression induced by WY-14,643. It is possible that the indirect inhibitory activity of WY-14,643 referred to in the study of Ledwith et al. (39) is an effect on GSH metabolism leading to increased GSH levels that have been shown in our study as well as others to inhibit COX activity. Indeed, there are numerous reports demonstrating the effect of peroxisome proliferators including WY-14,643 on GSH metabolism (40) .
The dissociation between COX-2 expression and PGE 2 levels in cells that were subjected to hypoxia could be the result of several factors operating under these conditions. One such factor is the availability of the substrate, arachidonic acid. However, experiments in which cells were prelabeled with arachidonic acid indicate that the levels of free arachidonic acid are, in fact, increased during hypoxia (data not shown). This is in accordance with reports which demonstrated that in many tissues ischemia/hypoxia leads to increased fatty acid release, including arachidonic acid, subsequent to activation of phospholipase A 2 (41) . One may argue that, when COX is inhibited, such increases may be shifted to other metabolic enzymes such as lipoxygenases and CYP monooxygenase. However, these cells do not express significant levels of either lipoxygenase or cytochrome P450 monooxygenase activity in culture under normoxia or hypoxia (data not shown). The small increase in PGE 2 accumulation may be due to the fact that the addition of exogenous arachidonic acid resulted in increased hydroperoxide levels, an essential requirement for COX catalytic activity (42) . There are several reports indicating the presence of hydroperoxides with various preparations of arachidonic acid (43) . It is noteworthy that PGE 2 levels in hypoxia-treated cells were essentially the same when either arachidonic acid was added or GSH was depleted. This suggests that the increased hydroperoxide level rather than substrate is the major factor contributing to the increased PGE 2 levels. With regard to hypoxia, factors such as lack of oxygen and increasing heme degradation due to rapid induction of HO-1 (44) are likely to be the major factors in limiting COX activity. Indeed, reoxygenation in the presence of heme restored COX activity in hypoxia-treated cells. On the other hand, the WY-14,643 inhibitory effect on COX activity was not removed by reoxygenation and heme. The apparent disparity between expression of COX-2 and endogenous levels of PGE 2 in the injured cells may have important pathophysiological and therapeutic implications. It is well documented that prolonged exposure of the corneal epithelium to hypoxia in the form of eye closure or contact lens wear leads to a pronounced inflammatory response (7) . It is also known that NSAIDs are only partially effective in treating ocular surface inflammation. Inasmuch as COX-2 is defined as an inflammatory gene, in the context of this type of injury and this tissue, it seems likely that its rapid induction does not lead to increased levels of PGE 2 , i.e. an increase in its expression does not yield a parallel increase in PGE 2 , further indicating that the inflammatory response in the corneal epithelium is not prostanoid-mediated under these conditions. Moreover, under these conditions, NSAIDs may intensify the inflammatory response by activating PPARs and subsequently amplifying the response via induction of CYP4B1 and production of the proinflammatory eicosanoids, 12-HETE and 12-HETrE. The increased production of the latter in the presence of NSAIDs may also result from shunting arachidonic acid to this pathway. To this end, preliminary studies have demonstrated induction of PPARs ␣ and ␤, COX-2, and CYP4B1 expression in corneal epithelium from rabbit eyes that were subjected to hypoxia via eye closure and contact lens wear; in this model the inflammatory response including edema, vasodilation, and neovascularization correlates with the duration of contact lens wear and is associated with increased synthesis of 12-HETE and 12-HETrE.
The events demonstrated in the cultured corneal epithelial cells may also occur in vivo not only in the cornea but also in other tissues where hypoxia produces an inflammatory response such as in vascular occlusion diseases. Moreover, the results of this study suggest that the therapeutic action of peroxisome proliferators such as fibrates may involve an increase in GSH levels and a decrease in the level of peroxidation. 
